Allopregnanolone and reproductive psychiatry: an overview

References

• Afroz, S., Shen, H., & Smith, S. S. (2017). Alpha4betadelta GABAA receptors reduce dendritic spine density in CA1 hippocampus and impair relearning ability of adolescent female mice: Effects of a GABA agonist and a stress steroid. Neuroscience, 347, 22–35. doi:10.1016/j.neuroscience.2017.01.051
   PubMed Web of Science ®Google Scholar
• Agis-Balboa, R. C., Guidotti, A., & Pinna, G. (2014). 5alpha-reductase type I expression is downregulated in the prefrontal cortex/Brodmann's area 9 (BA9) of depressed patients. Psychopharmacology (Berl), 231, 3569–3580. doi:10.1007/s00213-014-3567-5
   PubMed Web of Science ®Google Scholar
• Andreen, L., Sundstrom-Poromaa, I., Bixo, M., Andersson, A., Nyberg, S., & Backstrom, T. (2005). Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone. Psychoneuroendocrinology, 30, 212–224. doi:10.1016/j.psyneuen.2004.07.003
   PubMed Web of Science ®Google Scholar
• Backstrom, T., Bixo, M., Johansson, M., Nyberg, S., Ossewaarde, L., Ragagnin, G., … van Wingen, G. (2014). Allopregnanolone and mood disorders. Prog Neurobiol, 113, 88–94. doi:10.1016/j.pneurobio.2013.07.005
   PubMed Web of Science ®Google Scholar
• Backstrom, T., Bixo, M., & Stromberg, J. (2015). GABAA receptor-modulating steroids in relation to women's behavioral health. Curr Psychiatry Rep, 17, 92. doi:10.1007/s11920-015-0627-4
   PubMed Web of Science ®Google Scholar
• Backstrom, T., Haage, D., Lofgren, M., Johansson, I. M., Stromberg, J., Nyberg, S., … Bengtsson, S. K. (2011). Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience, 191, 46–54. doi:10.1016/j.neuroscience.2011.03.061
   PubMed Web of Science ®Google Scholar
• Barbaccia, M. L., Lello, S., Sidiropoulou, T., Cocco, T., Sorge, R. P., Cocchiarale, A., … Romanini, C. (2000). Plasma 5alpha-androstane-3alpha,17betadiol, an endogenous steroid that positively modulates GABA(A) receptor function, and anxiety: a study in menopausal women. Psychoneuroendocrinology, 25, 659–675. doi:10.1016/S0306-4530(00)00017-2
   PubMed Web of Science ®Google Scholar
• Bernardi, F., Hartmann, B., Casarosa, E., Luisi, S., Stomati, M., Fadalti, M., … Genazzani, A. R. (1998). High levels of serum allopregnanolone in women with premature ovarian failure. Gynecol Endocrinol, 12, 339–345. doi:10.3109/09513599809012836
   PubMed Web of Science ®Google Scholar
• Bernardi, F., Pieri, M., Stomati, M., Luisi, S., Palumbo, M., Pluchino, N., … Genazzani, A.R. (2003). Effect of different hormonal replacement therapies on circulating allopregnanolone and dehydroepiandrosterone levels in postmenopausal women. Gynecol Endocrinol, 17, 65–77. doi:10.1080/gye.17.1.65.77
   PubMed Web of Science ®Google Scholar
• Bixo, M., Johansson, M., Timby, E., Michalski, L., & Backstrom, T. (2018). Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder. J Neuroendocrinol, 30, e12553. doi:10.1111/jne.12553
   Web of Science ®Google Scholar
• Bloch, M., Schmidt, P. J., Danaceau, M., Murphy, J., Nieman, L., & Rubinow, D. R. (2000). Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry, 157, 924–930. doi:10.1176/appi.ajp.157.6.924
   PubMed Web of Science ®Google Scholar
• Bristot, G., Ascoli, B., Gubert, C., Panizzutti, B., Kapczinski, F., & Rosa, A. R. (2014). Progesterone and its metabolites as therapeutic targets in psychiatric disorders. Expert Opin Ther Targets, 18, 679–690. doi:10.1517/14728222.2014.897329
   PubMed Web of Science ®Google Scholar
• Burke, C. S., Susser, L. C., & Hermann, A. D. (2018). GABAA dysregulation as an explanatory model for late-onset postpartum depression associated with weaning and resumption of menstruation. Arch Womens Ment Health. Advance online publication. doi:10.1007/s00737-018-0871-9
   PubMed Web of Science ®Google Scholar
• Carver, C. M., & Reddy, D. S. (2013). Neurosteroid interactions with synaptic and extrasynaptic GABA(A) receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability. Psychopharmacology (Berl), 230, 151–188. doi:10.1007/s00213-013-3276-5
   PubMed Web of Science ®Google Scholar
• Chan, A. F., Mortola, J. F., Wood, S. H., & Yen, S. S. (1994). Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486. Obstet Gynecol, 84, 1001–1005.
   PubMed Web of Science ®Google Scholar
• Crowley, S. K., O’Buckley, T. K., Schiller, C. E., Stuebe, A., Morrow, A. L., & Girdler, S. S. (2016). Blunted neuroactive steroid and HPA axis responses to stress are associated with reduced sleep quality and negative affect in pregnancy: a pilot study. Psychopharmacology (Berl), 233, 1299–1310. doi:10.1007/s00213-016-4217-x
   PubMed Web of Science ®Google Scholar
• de Wit, H., Schmitt, L., Purdy, R., & Hauger, R. (2001). Effects of acute progesterone administration in healthy postmenopausal women and normally-cycling women. Psychoneuroendocrinology, 26, 697–710.
   PubMed Web of Science ®Google Scholar
• Deligiannidis, K. M., Kroll-Desrosiers, A. R., Mo, S., Nguyen, H. P., Svenson, A., Jaitly, N., … Shaffer, S. A. (2016). Peripartum neuroactive steroid and gamma-aminobutyric acid profiles in women at-risk for postpartum depression. Psychoneuroendocrinology, 70, 98–107. doi:10.1016/j.psyneuen.2016.05.010
   PubMed Web of Science ®Google Scholar
• Deligiannidis, K. M., Sikoglu, E. M., Shaffer, S. A., Frederick, B., Svenson, A. E., Kopoyan, A., … Moore, C. M. (2013). GABAergic neuroactive steroids and resting-state functional connectivity in postpartum depression: a preliminary study. J Psychiatr Res, 47, 816–828. doi:10.1016/j.jpsychires.2013.02.010
   PubMed Web of Science ®Google Scholar
• Fadalti, M., Petraglia, F., Luisi, S., Bernardi, F., Casarosa, E., Ferrari, E., … Bernasconi, S. (1999). Changes of serum allopregnanolone levels in the first 2 years of life and during pubertal development. Pediatr Res, 46, 323–327. doi:10.1203/00006450-199909000-00013
   PubMed Web of Science ®Google Scholar
• Genazzani, A. R., Petraglia, F., Bernardi, F., Casarosa, E., Salvestroni, C., Tonetti, A., … Luisi, M. (1998). Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. J Clin Endocrinol Metab, 83, 2099–2103. doi:10.1210/jcem.83.6.4905
   PubMed Web of Science ®Google Scholar
• Gilbert Evans, S. E., Ross, L. E., Sellers, E. M., Purdy, R. H., & Romach, M. K. (2005). 3alpha-reduced neuroactive steroids and their precursors during pregnancy and the postpartum period. Gynecol Endocrinol, 21, 268–279. doi:10.1080/09513590500361747
   PubMed Web of Science ®Google Scholar
• Girdler, S. S., Straneva, P. A., Light, K. C., Pedersen, C. A., & Morrow, A. L. (2001). Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry, 49, 788–797. doi:10.1016/S0006-3223(00)01044-1
   PubMed Web of Science ®Google Scholar
• Giuliani, F. A., Escudero, C., Casas, S., Bazzocchini, V., Yunes, R., Laconi, M.R., & Cabrera, R. (2013). Allopregnanolone and puberty: modulatory effect on glutamate and GABA release and expression of 3alpha-hydroxysteroid oxidoreductase in the hypothalamus of female rats. Neuroscience, 243, 64–75. doi:10.1016/j.neuroscience.2013.03.053
   PubMed Web of Science ®Google Scholar
• Guintivano, J., Sullivan, P. F., Stuebe, A. M., Penders, T., Thorp, J., Rubinow, D. R., & Meltzer-Brody, S. (2018). Adverse life events, psychiatric history, and biological predictors of postpartum depression in an ethnically diverse sample of postpartum women. Psychol Med, 48, 1190–1200. doi:10.1017/s0033291717002641
   PubMed Web of Science ®Google Scholar
• Hellgren, C., Akerud, H., Skalkidou, A., Backstrom, T., & Sundstrom-Poromaa, I. (2014). Low serum allopregnanolone is associated with symptoms of depression in late pregnancy. Neuropsychobiology, 69, 147–153. doi:10.1159/000358838
   PubMed Web of Science ®Google Scholar
• Hellgren, C., Comasco, E., Skalkidou, A., & Sundstrom-Poromaa, I. (2017). Allopregnanolone levels and depressive symptoms during pregnancy in relation to single nucleotide polymorphisms in the allopregnanolone synthesis pathway. Horm Behav, 94, 106–113. doi:10.1016/j.yhbeh.2017.06.008
   PubMed Web of Science ®Google Scholar
• Kanes, S., Colquhoun, H., Gunduz-Bruce, H., Raines, S., Arnold, R., Schacterle, A., … Meltzer-Brody, S. (2017). Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet, 390, 480–489. doi:10.1016/s0140-6736(17)31264-3
   PubMed Web of Science ®Google Scholar
• Klatzkin, R. R., Morrow, A. L., Light, K. C., Pedersen, C. A., & Girdler, S. S. (2006). Associations of histories of depression and PMDD diagnosis with allopregnanolone concentrations following the oral administration of micronized progesterone. Psychoneuroendocrinology, 31, 1208–1219. doi:10.1016/j.psyneuen.2006.09.002
   PubMed Web of Science ®Google Scholar
• Le Melledo, J. M., & Baker, G. (2004). Role of progesterone and other neuroactive steroids in anxiety disorders. Expert Rev Neurother, 4, 851–860. doi:10.1586/14737175.4.5.851
   PubMedGoogle Scholar
• Maguire, J., & Mody, I. (2008). GABA(A)R plasticity during pregnancy: relevance to postpartum depression. Neuron, 59, 207–213. doi:10.1016/j.neuron.2008.06.019
   PubMed Web of Science ®Google Scholar
• Martinez, P. E., Rubinow, D. R., Nieman, L. K., Koziol, D. E., Morrow, A. L., Schiller, C. E., … Schmidt, P. J. (2016). 5alpha-reductase inhibition prevents the luteal phase increase in plasma allopregnanolone levels and mitigates symptoms in women with premenstrual dysphoric disorder. Neuropsychopharmacology, 41, 1093–1102. doi:10.1038/npp.2015.246
   PubMed Web of Science ®Google Scholar
• McEvoy, K., Payne, J. L., & Osborne, L. M. (2018). Neuroactive steroids and perinatal depression: A review of recent literature. Curr Psychiatry Rep, 20, 78 doi:10.1007/s11920-018-0937-4
   PubMed Web of Science ®Google Scholar
• Meltzer-Brody, S., Colquhoun, H., Riesenberg, R., Epperson, C. N., Deligiannidis, K. M., Rubinow, D. R., … Kanes, S. (2018). Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet, 392, 1058–1070. doi:10.1016/s0140-6736(18)31551-4
   PubMed Web of Science ®Google Scholar
• Morgan, M. L., Rapkin, A. J., Biggio, G., Serra, M., Pisu, M. G., & Rasgon, N. (2010). Neuroactive steroids after estrogen exposure in depressed postmenopausal women treated with sertraline and asymptomatic postmenopausal women. Arch Womens Ment Health, 13, 91–98. doi:10.1007/s00737-009-0106-1
   PubMed Web of Science ®Google Scholar
• Morrow, A. L. (2007). Recent developments in the significance and therapeutic relevance of neuroactive steroids–Introduction to the special issue. Pharmacol Ther, 116, 1–6. doi:10.1016/j.pharmthera.2007.04.003
   PubMed Web of Science ®Google Scholar
• Nguyen, T. V., Reuter, J. M., Gaikwad, N. W., Rotroff, D. M., Kucera, H. R., Motsinger-Reif, A., … Schmidt, P. J. (2017). The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback. Transl Psychiatry, 7, e1193. doi:10.1038/tp.2017.146
   PubMed Web of Science ®Google Scholar
• Nyberg, S., Backstrom, T., Zingmark, E., Purdy, R. H., & Poromaa, I. S. (2007). Allopregnanolone decrease with symptom improvement during placebo and gonadotropin-releasing hormone agonist treatment in women with severe premenstrual syndrome. Gynecol Endocrinol, 23, 257–266. doi:10.1080/09513590701253511
   PubMed Web of Science ®Google Scholar
• Osborne, L. M., Gispen, F., Sanyal, A., Yenokyan, G., Meilman, S., & Payne, J. L. (2017). Lower allopregnanolone during pregnancy predicts postpartum depression: An exploratory study. Psychoneuroendocrinology, 79, 116–121. doi:10.1016/j.psyneuen.2017.02.012
   PubMed Web of Science ®Google Scholar
• Ossewaarde, L., Hermans, E. J., van Wingen, G. A., Kooijman, S. C., Johansson, I.-M., Bäckström, T., & Fernández, G. (2010). Neural mechanisms underlying changes in stress-sensitivity across the menstrual cycle. Psychoneuroendocrinology, 35, 47–55. doi:10.1016/j.psyneuen.2009.08.011
   PubMed Web of Science ®Google Scholar
• Predieri, B., Luisi, S., Casarosa, E., De Simone, M., Balli, F., Bernasconi, S., … Iughetti, L. (2007). High basal serum allopregnanolone levels in overweight girls. Int J Obes (Lond), 31, 543–549. doi:10.1038/sj.ijo.0803406
   PubMed Web of Science ®Google Scholar
• Rouge-Pont, F., Mayo, W., Marinelli, M., Gingras, M., Le Moal, M., & Piazza, P. V. (2002). The neurosteroid allopregnanolone increases dopamine release and dopaminergic response to morphine in the rat nucleus accumbens. Eur J Neurosci, 16, 169–173. doi:10.1046/j.1460-9568.2002.02084.x
   PubMed Web of Science ®Google Scholar
• Rupprecht, R. (2003). Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology, 28, 139–168. doi:10.1016/S0306-4530(02)00064-1
   PubMed Web of Science ®Google Scholar
• Schiller, C. E., Schmidt, P. J., & Rubinow, D. R. (2014). Allopregnanolone as a mediator of affective switching in reproductive mood disorders. Psychopharmacology (Berl), 231, 3557–3567. doi:10.1007/s00213-014-3599-x
   PubMed Web of Science ®Google Scholar
• Schmidt, P. J., Nieman, L. K., Danaceau, M. A., Adams, L. F., & Rubinow, D. R. (1998). Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med, 338, 209–216. doi:10.1056/nejm199801223380401
   PubMed Web of Science ®Google Scholar
• Schule, C., Nothdurfter, C., & Rupprecht, R. (2014). The role of allopregnanolone in depression and anxiety. Prog Neurobiol, 113, 79–87. doi:10.1016/j.pneurobio.2013.09.003
   PubMed Web of Science ®Google Scholar
• Shen, H., Gong, Q. H., Aoki, C., Yuan, M., Ruderman, Y., Dattilo, M., … Smith, S. S. (2007). Reversal of neurosteroid effects at alpha4beta2delta GABAA receptors triggers anxiety at puberty. Nat Neurosci, 10, 469–477. doi:10.1038/nn1868
   PubMed Web of Science ®Google Scholar
• Slopien, R., Pluchino, N., Warenik-Szymankiewicz, A., Sajdak, S., Luisi, M., Drakopoulos, P., & Genazzani, A. R. (2018). Correlation between allopregnanolone levels and depressive symptoms during late menopausal transition and early postmenopause. Gynecol Endocrinol, 34, 144–147. doi:10.1080/09513590.2017.1371129
   PubMed Web of Science ®Google Scholar
• Syan, S. K., Minuzzi, L., Costescu, D., Smith, M., Allega, O. R., Coote, M., … Frey, B. N. (2017). Influence of endogenous estradiol, progesterone, allopregnanolone, and dehydroepiandrosterone sulfate on brain resting state functional connectivity across the menstrual cycle. Fertil Steril, 107, 1246–1255. e1244. doi:10.1016/j.fertnstert.2017.03.021
   PubMed Web of Science ®Google Scholar
• Timby, E., Backstrom, T., Nyberg, S., Stenlund, H., Wihlback, A. N., & Bixo, M. (2016). Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls-a pilot study. Psychopharmacology (Berl), 233, 2109–2117. doi:10.1007/s00213-016-4258-1
   PubMed Web of Science ®Google Scholar
• Uzunova, V., Ceci, M., Kohler, C., Uzunov, D. P., & Wrynn, A. S. (2003). Region-specific dysregulation of allopregnanolone brain content in the olfactory bulbectomized rat model of depression. Brain Res, 976, 1–8. doi:10.1016/S0006-8993(03)02577-0
   PubMed Web of Science ®Google Scholar
• Uzunova, V., Wrynn, A. S., Kinnunen, A., Ceci, M., Kohler, C., & Uzunov, D. P. (2004). Chronic antidepressants reverse cerebrocortical allopregnanolone decline in the olfactory-bulbectomized rat. Eur J Pharmacol, 486, 31–34. doi:10.1016/j.ejphar.2003.12.002
   PubMed Web of Science ®Google Scholar